Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement
24 juil. 2023 07h30 HE
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage...
Completion of Enrolment and Treatment in the Phase 1 Study of MTX110 in the Treatment of Children with Newly Diagnosed Diffuse Midline Gliomas (DMGs)
10 juil. 2023 08h00 HE
|
Biodexa Pharmaceuticals PLC
10 July 2023 Biodexa Ltd(“Biodexa” or the “Company”) Completion of Enrolment and Treatment in the Phase 1 Study of MTX110 in theTreatment of Children with Newly Diagnosed Diffuse Midline Gliomas...
Results of Appeal of Delisting Determination
06 juil. 2023 16h30 HE
|
Biodexa Pharmaceuticals PLC
6 July 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Results of Appeal of Delisting Determination Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical...
Publication of Manuscript from the PNOC015 (a.k.a. MTD-201) Study in Patients with Diffuse Midline Glioma (DMG)
06 juil. 2023 08h15 HE
|
Biodexa Pharmaceuticals PLC
6 July 2023 Biodexa Ltd(“Biodexa” or the “Company”) Publication of Manuscript from the PNOC015 (a.k.a. MTD-201) Study in Patients with Diffuse Midline Glioma (DMG) Biodexa Pharmaceuticals PLC...
ADR Ratio Change
22 juin 2023 16h15 HE
|
Biodexa Pharmaceuticals PLC
22 June 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company developing a pipeline of...
Appeal of Delisting Determination
20 juin 2023 08h00 HE
|
Biodexa Pharmaceuticals PLC
20 June 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Appeal of Delisting Determination Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company...
Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy
12 juin 2023 07h30 HE
|
Vaccitech plc
OXFORD, United Kingdom, June 12, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of...
Lung Cancer Treatment Market to exceed USD 49.4 billion by 2032, Says Graphical Research Powered by GMI
31 mai 2023 18h30 HE
|
Graphical Research
Selbyville, Delaware, May 31, 2023 (GLOBE NEWSWIRE) -- Lung Cancer Treatment Market size is expected to surpass USD 49.4 billion by 2032. The rising awareness regarding the treatments of chronic...
United States Squamous-Cell Lung Cancer (SqC-LC) Epidemiology Report 2022-2042
29 mai 2023 08h28 HE
|
Research and Markets
Dublin, May 29, 2023 (GLOBE NEWSWIRE) -- The "Squamous-Cell Lung Cancer in the United States, 2022-2042: Cancer Populations USA Report and Data Dashboard" report has been added to ...
Biodexa Pharmaceuticals PLC Announces Closing of $3.32 Million Registered Direct Offering
26 mai 2023 16h05 HE
|
Biodexa Pharmaceuticals PLC
26 May 2023 Biodexa Pharmaceuticals PLC Announces Closing of $3.32 Million Registered Direct Offering Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX), a...